A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan

Soo-Kyung ChoDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Ryoko SakaiDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Toshihiro NankiDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Ryuji KoikeDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Clinical Research Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan

Kaori WatanabeDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Hayato YamazakiDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Hayato NagasawaDepartment of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Fukuoka, Japan

Atsuo NakajimaDepartment of Rheumatology, Tokyo Metropolitan Police Hospital, Tokyo, Japan

Shinsuke YasudaDepartment of Internal Medicine II, Hokkaido University, Graduate School of Medicine, Sapporo, Japan

Atsushi IhataDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Kazuhiko EzawaDepartment of Internal medicine, Kurashiki Kousai Hospital, Kurashiki, Japan

Soyoung WonClinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Chan-Bum ChoiHanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Yoon-Kyoung SungHanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Tae-Hwan KimHanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Jae-Bum JunHanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Dae-Hyun YooHanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Nobuyuki MiyasakaDepartment of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, Tokyo, Japan

Sang-Cheol BaeHanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea

Masayoshi HarigaiDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, JapanCorrespondence[email protected]

, for the RESEARCH investigators & the REAL Study Group show all

A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan

Supplementary Figures 1 and 2

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan

Supplementary Figures 1 and 2

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date